Roche Holding AG revealed plans to launch its sequencing by expansion technology next year, raising the possibility that ...

Though it’s been used off-label for more than three decades to treat cerebrotendinous xanthomatosis, Mirum Pharmaceuticals Inc.’s chenodiol gained an official U.S. FDA nod Feb. 21 as the first drug ...

Aptamers are single-stranded DNA or RNA molecules with unique 3D structures that allow for specific binding to a wide variety of ions and molecules. Due to their unique properties, aptamers have been ...

A new version of Evo, the AI developed at the Arc Institute that can be used to design genomes as long as that of a bacterium, has been retrained with the DNA sequences of three domains of life – ...

EG 427 SAS has closed a €27 million (US$28.3 million) series B round, which will fund it to completion of the first clinical ...

The lung and thrombosis may play a key role in cancer and metastasis progression, according to a collaborative study led by ...

The longstanding ambition of developing an inhaled gene therapy for cystic fibrosis has taken a step forward, with the start of a phase I/II trial of a product using a novel pseudotyped viral vector ...

Researchers from Tikkunlev Therapeutics Inc. and the University of Utah have presented preclinical data on TLT-101, a gene therapy consisting of an adeno-associated virus serotype 9 (AAV9) vector ...

Artificial intelligence (AI) technology developer Genesis Therapeutics Inc. has brought in another larger partner to go on a search for the right therapeutic small molecules. The company is getting an ...

Researchers from Tianjin University have published data regarding development and preclinical characterization of a new anti-PD-L1/CD40 bispecific antibody (BsAb), BA-4415, designed to activate CD40 ...

The first patenting from Theta Neurotech Inc. sees the company’s co-founders describe their development of a wearable earpiece that uses an electroencephalography technology and machine learning ...

Hangzhou Zhongmei Huadong Pharmaceutical Co. Ltd. has described molecular glue compounds acting as eukaryotic peptide chain release factor GTP-binding subunit ERF3A (GSPT1) degradation inducers ...